Compare NCLH & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NCLH | OLMA |
|---|---|---|
| Founded | 1966 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7B | 2.6B |
| IPO Year | 2013 | 2020 |
| Metric | NCLH | OLMA |
|---|---|---|
| Price | $22.73 | $25.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 6 |
| Target Price | $28.11 | ★ $40.50 |
| AVG Volume (30 Days) | ★ 16.5M | 2.6M |
| Earning Date | 11-04-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.76 | N/A |
| EPS | ★ 1.40 | N/A |
| Revenue | ★ $9,692,558,000.00 | N/A |
| Revenue This Year | $6.85 | N/A |
| Revenue Next Year | $10.26 | N/A |
| P/E Ratio | $15.97 | ★ N/A |
| Revenue Growth | ★ 3.59 | N/A |
| 52 Week Low | $14.21 | $2.86 |
| 52 Week High | $29.29 | $36.26 |
| Indicator | NCLH | OLMA |
|---|---|---|
| Relative Strength Index (RSI) | 61.87 | 48.92 |
| Support Level | $22.15 | $25.85 |
| Resistance Level | $24.32 | $36.26 |
| Average True Range (ATR) | 0.76 | 2.22 |
| MACD | 0.07 | -1.28 |
| Stochastic Oscillator | 56.27 | 9.02 |
Norwegian Cruise Line is the world's third-largest publicly traded cruise company by berths (around 71,000). It operates 34 ships across three brands—Norwegian, Oceania, and Regent Seven Seas—offering both freestyle and luxury cruising. The company redeployed its entire fleet as of May 2022. With 13 passenger vessels on order among its brands through 2036, representing 38,400 incremental berths, Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sails to around 700 global destinations.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.